Dirk Van Gysel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dirk Van Gysel has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Hannelore De Maeseneer
Department of Pediatrics O.L. Vrouw Hospital Aalst Aalst Belgium
6 shared publications- Arnold P. Oranje
Department of Pediatrics, Erasmus MC, Sophia Children's Hospital, Rotterdam, The Netherlands
4 shared publications - Julia Nowowiejska
Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland
4 shared publications Marieke Donné
Department of Pediatrics, O.L.Vrouw Hospital, Aalst, Belgium
4 shared publications- Vincenzo Piccolo
Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine University of Campania Luigi Vanvitelli Naples Italy
4 shared publications Erenik Doli
O.L.Vrouw Hospital
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Update on Pediatric Dermoscopy in Lighter Phototypes: Changes During the Evolution of the Diseases and Clues Predicting Response to Treatments
Dermoscopy is a noninvasive tool that enables the visualization of skin lesions with magnification, allowing for more accurate diagnosis. Over the years, it has evolved from a utility in differentiation between malignant and benign neoplasms to administration in the vascular, inflammatory, and infectious dermatoses. Dermoscopy is a very important diagnostic tool, especially in pediatric patients, due to its noninvasive and painless character. It not only enables the correct diagnosis but also may provide some prognostic clues, and after the treatment, it allows the dermatologist to observe the progress of therapy. The review aims at the discussion of the use of dermoscopy in the management of pediatric non‐neoplastic dermatoses, namely, differential diagnosis, prognosis assessment, adjusting the treatment, and therapy outcome monitoring.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessUpdate on Pediatric Dermoscopy in Lighter Phototypes: Changes During the Evolution of the Diseases and Clues Predicting Response to Treatments
Dermoscopy is a noninvasive tool that enables the visualization of skin lesions with magnification, allowing for more accurate diagnosis. Over the years, it has evolved from a utility in differentiation between malignant and benign neoplasms to administration in the vascular, inflammatory, and infectious dermatoses. Dermoscopy is a very important diagnostic tool, especially in pediatric patients, due to its noninvasive and painless character. It not only enables the correct diagnosis but also may provide some prognostic clues, and after the treatment, it allows the dermatologist to observe the progress of therapy. The review aims at the discussion of the use of dermoscopy in the management of pediatric non‐neoplastic dermatoses, namely, differential diagnosis, prognosis assessment, adjusting the treatment, and therapy outcome monitoring.
- 21 February 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (9) , 1701-1703
Topical Sirolimus Treatment of Recurrent Lymphangioma Circumscriptum
- 21 February 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (9) , 1701-1703
Topical Sirolimus Treatment of Recurrent Lymphangioma Circumscriptum
- Open Access
- 29 January 2025
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 15 (1) , 4738
Petechiae and Limb Weakness in a 12-Year-Old Boy
- 29 January 2025
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 15 (1) , 4738
Open AccessPetechiae and Limb Weakness in a 12-Year-Old Boy
- 17 October 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (5) , 934-935
Nilotinib‐induced lichen planopilaris—a case report and review of the literature
- 17 October 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (5) , 934-935
Nilotinib‐induced lichen planopilaris—a case report and review of the literature
- 24 April 2024
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 20 (5) , 435-443
Sturge–Weber syndrome: an update for the pediatrician
Background Sturge–Weber syndrome (SWS) is a rare congenital neurocutaneous disorder characterized by the simultaneous presence of both cutaneous and extracutaneous capillary malformations. SWS usually presents as a facial port-wine birthmark, with a varying presence of leptomeningeal capillary malformations and ocular vascular abnormalities. The latter may lead to significant neurological and ocular morbidity such as epilepsy and glaucoma. SWS is most often caused by a somatic mutation involving the G protein subunit alpha Q or G protein subunit alpha 11 gene causing various alterations in downstream signaling pathways. We specifically conducted a comprehensive review focusing on the current knowledge of clinical practices, the latest pathophysiological insights, and the potential novel therapeutic avenues they provide. Data sources A narrative, non-systematic review of the literature was conducted, combining expert opinion with a balanced review of the available literature. A search of PubMed, Google Scholar and Embase was conducted, using keywords “Sturge–Weber Syndrome” OR “SWS”, “Capillary malformations”, “G protein subunit alpha 11” OR “G protein subunit alpha Q”. Results One of the hallmark features of SWS is the presence of a port-wine birthmark at birth, and forehead involvement is most indicative for SWS. The most common ocular manifestations of SWS are glaucoma and choroidal hemangioma. Glaucoma presents in either in infancy (0–3 years of age) or later in life. Neurological complications are common in SWS, occurring in about 70%–80% of patients, with seizures being the most common one. SWS significantly impacts the quality of life for patients and their families, and requires a multidisciplinary approach for diagnosis and treatment. Currently, no disease-modifying therapies exist, and treatment is mostly focused on symptoms or complications as they arise. Conclusions SWS remains a complex and heterogeneous disorder. Further research is needed to optimize diagnostic and therapeutic strategies, and to translate insights from molecular pathogenesis to clinical practice. Graphical Abstract
- 24 April 2024
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 20 (5) , 435-443
Sturge–Weber syndrome: an update for the pediatrician
Background Sturge–Weber syndrome (SWS) is a rare congenital neurocutaneous disorder characterized by the simultaneous presence of both cutaneous and extracutaneous capillary malformations. SWS usually presents as a facial port-wine birthmark, with a varying presence of leptomeningeal capillary malformations and ocular vascular abnormalities. The latter may lead to significant neurological and ocular morbidity such as epilepsy and glaucoma. SWS is most often caused by a somatic mutation involving the G protein subunit alpha Q or G protein subunit alpha 11 gene causing various alterations in downstream signaling pathways. We specifically conducted a comprehensive review focusing on the current knowledge of clinical practices, the latest pathophysiological insights, and the potential novel therapeutic avenues they provide. Data sources A narrative, non-systematic review of the literature was conducted, combining expert opinion with a balanced review of the available literature. A search of PubMed, Google Scholar and Embase was conducted, using keywords “Sturge–Weber Syndrome” OR “SWS”, “Capillary malformations”, “G protein subunit alpha 11” OR “G protein subunit alpha Q”. Results One of the hallmark features of SWS is the presence of a port-wine birthmark at birth, and forehead involvement is most indicative for SWS. The most common ocular manifestations of SWS are glaucoma and choroidal hemangioma. Glaucoma presents in either in infancy (0–3 years of age) or later in life. Neurological complications are common in SWS, occurring in about 70%–80% of patients, with seizures being the most common one. SWS significantly impacts the quality of life for patients and their families, and requires a multidisciplinary approach for diagnosis and treatment. Currently, no disease-modifying therapies exist, and treatment is mostly focused on symptoms or complications as they arise. Conclusions SWS remains a complex and heterogeneous disorder. Further research is needed to optimize diagnostic and therapeutic strategies, and to translate insights from molecular pathogenesis to clinical practice. Graphical Abstract
- 15 April 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (5) , 915-917
A 10‐year‐old girl with gray‐brown patches in the axillary and inguinal folds
- 15 April 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (5) , 915-917
A 10‐year‐old girl with gray‐brown patches in the axillary and inguinal folds
- 8 March 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (6) , 824-826
Myofibroma of infancy and its mimickers
- 8 March 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (6) , 824-826
Myofibroma of infancy and its mimickers
- 29 January 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (1) , 182-183
Incontinentia pigmenti Stage 1 is not simply vesiculo‐bullous but vesiculo‐pustular
Incontinentia pigmenti (IP) is a rare X‐linked dominant, male‐lethal disorder characterized by pathognomic skin lesions. As described in the literature the typical cutaneous changes follow the pattern of Blaschko's lines and develop in four stages that usually start at birth. Stage 1 is called vesicular, bullous or inflammatory. The vesicles are rapidly filled with eosinophils and thus turn into pustules. Thus, the term “pustular” is relevant to the first phase of IP, and the stage can be considered as “vesiculopustular/inflammatory” to be more precise than “vesicular” or “bullous.”
- 29 January 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (1) , 182-183
Incontinentia pigmenti Stage 1 is not simply vesiculo‐bullous but vesiculo‐pustular
Incontinentia pigmenti (IP) is a rare X‐linked dominant, male‐lethal disorder characterized by pathognomic skin lesions. As described in the literature the typical cutaneous changes follow the pattern of Blaschko's lines and develop in four stages that usually start at birth. Stage 1 is called vesicular, bullous or inflammatory. The vesicles are rapidly filled with eosinophils and thus turn into pustules. Thus, the term “pustular” is relevant to the first phase of IP, and the stage can be considered as “vesiculopustular/inflammatory” to be more precise than “vesicular” or “bullous.”
- 28 November 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (2) , 289-291
Capillary malformations in a child caused by a novel HRAS mutation
A 6‐year‐old boy with multiple capillary malformations of the port‐wine birthmark (PWB) type on the right leg since birth presented with a varicose vein and segmental overgrowth of the affected leg. Genetic testing on affected skin confirmed the presence of a somatic novel pathogenic HRAS 30 bp in‐frame duplication/insertion in the switch II domain. This case illustrates the phenotypic overlap of different genotypes and shows that somatic HRAS pathogenic variants, especially in‐frame duplications/insertions, must be added to the list of the underlying causes in capillary malformations.
- 28 November 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (2) , 289-291
Capillary malformations in a child caused by a novel HRAS mutation
A 6‐year‐old boy with multiple capillary malformations of the port‐wine birthmark (PWB) type on the right leg since birth presented with a varicose vein and segmental overgrowth of the affected leg. Genetic testing on affected skin confirmed the presence of a somatic novel pathogenic HRAS 30 bp in‐frame duplication/insertion in the switch II domain. This case illustrates the phenotypic overlap of different genotypes and shows that somatic HRAS pathogenic variants, especially in‐frame duplications/insertions, must be added to the list of the underlying causes in capillary malformations.
- 5 October 2023
- Published by Springer Nature
- p. 639-650
Mastocytosis